Nitric Oxide and Cancer Therapy: the Emperor Has NO Clothes

Overview

Journal Curr Pharm Des

Publisher Bentham Science Publishers

Date 2010 Mar 19

PMID 20236067

Citations 58

Authors

Jason R Hickok

Douglas D Thomas

Affiliations

Soon will be listed here.

Abstract

The role of nitric oxide (NO()) as a mediator of cancer phenotype has led researchers to investigate strategies for manipulating in vivo production and exogenous delivery of this molecule for therapeutic gain. Unfortunately, NO() serves multiple functions in cancer physiology. In some instances, NO() or nitric oxide synthase (NOS) levels correlate with tumor suppression and in other cases they are related to tumor progression and metastasis. Understanding this dichotomy has been a great challenge for researchers working in the field of NO() and cancer therapy. Due to the unique chemical and biochemical properties of NO(), it's interactions with cellular targets and the subsequent downstream signaling events can be vastly different based upon tumor heterogeneity and microenvironment. Simple explanations for the vast range of NO-correlated behaviors will continue to produce conflicting information about the relevance of NO() and cancer. Paying considerable attention to the chemical properties of NO() and the methodologies being used will remove many of the discrepancies in the field and allow for in depth understanding of when NO-based chemotherapeutics will have beneficial outcomes.

Citing Articles

Exploring the role of oral bacteria in oral cancer: a narrative review.

Mivehchi H, Eskandari-Yaghbastlo A, Pour Bahrami P, Elhami A, Faghihinia F, Nejati S Discov Oncol. 2025; 16(1):242.

PMID: 40009328 PMC: 11865422. DOI: 10.1007/s12672-025-01998-2.

Nitric oxide inhibits ten-eleven translocation DNA demethylases to regulate 5mC and 5hmC across the genome.

Palczewski M, Kuschman H, Hoffman B, Kathiresan V, Yang H, Glynn S Nat Commun. 2025; 16(1):1732.

PMID: 39966373 PMC: 11836389. DOI: 10.1038/s41467-025-56928-1.

Fabrication and Optimization of Poly(ε-caprolactone) Microspheres Loaded with S-Nitroso-N-Acetylpenicillamine for Nitric Oxide Delivery.

Alvi S, Pracha N, Shalaan M, Dholaniya P, Mergaye M, Sridharan D Biomedicines. 2024; 12(6).

PMID: 38927571 PMC: 11201505. DOI: 10.3390/biomedicines12061363.

Hyaluronic Acid-Coated Silica Nanoparticles for Targeted Delivery of Nitric Oxide to Cancer Cells.

Grayton Q, Phan T, Kussatz C, Schoenfisch M ACS Appl Bio Mater. 2024; 7(6):3796-3809.

PMID: 38776418 PMC: 11546759. DOI: 10.1021/acsabm.4c00171.

Hemin as a Molecular Probe for Nitric Oxide Detection in Physiological Solutions: Experimental and Theoretical Assessment.

Alsharabasy A, Farras P, Pandit A Anal Chem. 2024; 96(19):7763-7771.

PMID: 38699865 PMC: 11099896. DOI: 10.1021/acs.analchem.4c01516.

References

Thomas D, Ridnour L, Isenberg J, Flores-Santana W, Switzer C, Donzelli S . The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med. 2008; 45(1):18-31. PMC: 2572721. DOI: 10.1016/j.freeradbiomed.2008.03.020. View

Dunlap T, Abdul-Hay S, Chandrasena R, Hagos G, Sinha V, Wang Z . Nitrates and NO-NSAIDs in cancer chemoprevention and therapy: in vitro evidence querying the NO donor functionality. Nitric Oxide. 2008; 19(2):115-24. PMC: 2572831. DOI: 10.1016/j.niox.2008.04.013. View

Coulter J, McCarthy H, Xiang J, Roedl W, Wagner E, Robson T . Nitric oxide--a novel therapeutic for cancer. Nitric Oxide. 2008; 19(2):192-8. DOI: 10.1016/j.niox.2008.04.023. View

Yasuda H . Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric Oxide. 2008; 19(2):205-16. DOI: 10.1016/j.niox.2008.04.026. View

Wink D, Ridnour L, Hussain S, Harris C . The reemergence of nitric oxide and cancer. Nitric Oxide. 2008; 19(2):65-7. PMC: 2565861. DOI: 10.1016/j.niox.2008.05.003. View

Simeone A, McMurtry V, Nieves-Alicea R, Saavedra J, Keefer L, Johnson M . TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells. Breast Cancer Res. 2008; 10(3):R44. PMC: 2481491. DOI: 10.1186/bcr2095. View

Hussain S, He P, Subleski J, Hofseth L, Trivers G, Mechanic L . Nitric oxide is a key component in inflammation-accelerated tumorigenesis. Cancer Res. 2008; 68(17):7130-6. PMC: 2576291. DOI: 10.1158/0008-5472.CAN-08-0410. View

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

Kawamori T, Takahashi M, Watanabe K, Ohta T, Nakatsugi S, Sugimura T . Suppression of azoxymethane-induced colonic aberrant crypt foci by a nitric oxide synthase inhibitor. Cancer Lett. 2000; 148(1):33-7. DOI: 10.1016/s0304-3835(99)00310-9. View

10.

Jadeski L, Hum K, Chakraborty C, Lala P . Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer. 2000; 86(1):30-9. DOI: 10.1002/(sici)1097-0215(20000401)86:1<30::aid-ijc5>3.0.co;2-i. View

11.

Hoffman P, Mauer A, Vokes E . Lung cancer. Lancet. 2000; 355(9202):479-85. DOI: 10.1016/S0140-6736(00)82038-3. View

12.

Schmucker D, Clemens J, Shu H, Worby C, Xiao J, Muda M . Drosophila Dscam is an axon guidance receptor exhibiting extraordinary molecular diversity. Cell. 2000; 101(6):671-84. DOI: 10.1016/s0092-8674(00)80878-8. View

13.

Hogg N . Biological chemistry and clinical potential of S-nitrosothiols. Free Radic Biol Med. 2000; 28(10):1478-86. DOI: 10.1016/s0891-5849(00)00248-3. View

14.

Sandau K, Faus H, Brune B . Induction of hypoxia-inducible-factor 1 by nitric oxide is mediated via the PI 3K pathway. Biochem Biophys Res Commun. 2000; 278(1):263-7. DOI: 10.1006/bbrc.2000.3789. View

15.

Ekmekcioglu S, Ellerhorst J, Smid C, Prieto V, Munsell M, Buzaid A . Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res. 2001; 6(12):4768-75. View

16.

Thomas D, Liu X, Kantrow S, Lancaster Jr J . The biological lifetime of nitric oxide: implications for the perivascular dynamics of NO and O2. Proc Natl Acad Sci U S A. 2001; 98(1):355-60. PMC: 14594. DOI: 10.1073/pnas.98.1.355. View

17.

Sandau K, Fandrey J, Brune B . Accumulation of HIF-1alpha under the influence of nitric oxide. Blood. 2001; 97(4):1009-15. DOI: 10.1182/blood.v97.4.1009. View

18.

Shekhar M, Werdell J, Santner S, Pauley R, Tait L . Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res. 2001; 61(4):1320-6. View

19.

Johnson J, Decker S, Zaharevitz D, Rubinstein L, Venditti J, SCHEPARTZ S . Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001; 84(10):1424-31. PMC: 2363645. DOI: 10.1054/bjoc.2001.1796. View

20.

Derynck R, Akhurst R, Balmain A . TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001; 29(2):117-29. DOI: 10.1038/ng1001-117. View